Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib)...
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER )
Also on site :
- Greta Thunberg bizarrely claims she DIDN’T KNOW her ‘Freedom Flotilla’ crewmates had shown support for Hamas & Hezbollah
- Trump says reconciliation with Musk is possible in interview before Tesla boss’s apology
- Waste accumulation threatens health of al-Kashkiya residents in Deir Ezzor